Sergeja Lebar

Lipid nanoparticles (LNPs) have emerged as the predominant delivery platform for nucleic acid therapeutics, enabling transformative clinical applications ranging from prophylactic mRNA vaccines to in vivo gene editing, gene therapy, protein replacement therapies, and personalized cancer immunotherapies [1–4]. As LNP formulations become increasingly complex, incorporating novel ionizable lipids, targeting ligands, and multi-component payloads—the analytical challenges expand proportionally.

Cell & Gene Therapy Insights 2023; 9(9), 1231–1247 DOI: 10.18609/cgti.2023.161 Rapid advancement of mRNA technology, as a response to the COVID-19 crisis, prompted an increased need for precise analytical methods to support the fast-paced mRNA process development.